A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

NCT02418819 | Completed Phase 1 Results

• 1 other identifier: B7441007
• Study Type: interventional
• Target: 103
• Locations: 1 country
• Sites: 6

Brief Summary

This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in subjects with schizophrenia.

Conditions

Schizophrenia

Outcome Measures

Primary Outcomes (7)

• Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

  An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect. Any events occurring following start of treatment or increasing in severity were counted as treatment emergent. AEs included both serious and non-serious AEs.

  Baseline up to 7-10 days after last dose of study drug, up to 26 days

• Number of Participants With Supine and Standing Vital Signs Meeting Categorical Summarization Criteria

  Vital Signs tests included systolic and diastolic blood pressure (BP) and pulse rate of seated supine and standing . Vital signs categorical summarization criteria were 1), supine and standing BP: systolic (SBP) greater than or equal to (\>=) 30 millimeters of mercury (mm Hg) change from baseline, systolic less than (\<) 90 mm Hg; diastolic BP (DBP) \>=20 mm Hg change from baseline, diastolic \<50 mm Hg; 2), supine and standing pulse rate \<40 or greater than (\>) 120 beats per minute (bpm).

  Baseline up to 7-10 days after last dose of study drug, up to 26 days

• Number of Participants With Electrocardiogram (ECG) (Standard 12-Lead) Data Meeting Categorical Summarization Criteria

  ECG categorical summarization criteria were 1), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS interval): more than or equal to (\>=) 200 milliseconds (msec); for percent change(PChg), \>=25 percent (%) increase when baseline (b)\>100 msec; or increase \>=50% when b less than or equal to (\<=)100 msec; 2), the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): \>=300 msec; \>=25percent (%) increase when b \>200 msec; or increase \>=50% when b \<=200 msec; 3), time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTcF interval): absolute value \>=450 - \<480 msec, \>=480-\<500 msec and \>=500 msec; increase from b \>=30 - \<60 and \>=60 msec

  Baseline up to 7-10 days after last dose of study drug, up to 26 days

• Number of Participants With Blood and Urine Safety Laboratory Test Abnormalities

  The total number of participants with blood and urine laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis, and some other tests.

  Baseline up to Day 15

• Number of Participants With New Onset and Worsening of Post Baseline Suicidality in Columbia Suicide Severity Rating Scale (C-SSRS) on Day 1, Day 7 and Follow-up.

  The C-SSRS was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. Versions were available for Screening/Baseline and follow-up visits. Post-baseline suicidality was displayed without regard to baseline and as new onset or worsening relative to baseline. A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment. A participant was considered to have a worsening of suicidality if the participant moved to a lower numbered Columbia Classification Algorithm of Suicide Assessment (C-CASA) category (observed in categories 1-4) than was reported at baseline.

  Baseline, Days 1,7 and follow-up (7-10 days after last dose of study drug, up to 26 days)

• Change From Baseline to Day 13 of Wechsler Memory Scale (WMS III) Spatial Span + Letter Number Span Composite Score (Working Memory Domain)

  MCCB measures cognitive function across cognitive domains and is comprised of 10 independent tests assessing 7 cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition). A subset of the MCCB cognitive domain was used to assess working memory of participants. Total score range of this subset ranges from 40 (minimum score) to 60 (maximum score), with higher scores indicating better cognitive function.

  Baseline, Day 13

• Change From Baseline in Blood Oxygen Level Dependent (BOLD) fMRI Activation Parameter Estimates (Z-scores) in Anterior Ventral Striatum Region of Interest (ROI) for the Contrast of Cue Gain > Cue No Gain in Monetary Incentive Delay (MID) Task on Day 15

  MRI parameter estimates refer to the 90th percentile Z-statistics across all voxels within the Region of Interest (ROI). This task provided a measure of reward anticipation and reward consummation. One of 3 shapes was presented on the screen (each uniquely associated with gain, loss and neutral) as a cue, and participants were instructed to respond to each cue, using their dominant hand, by pressing in response to a subsequent target that appeared for a variable length of time. Baseline was defined as Day 0 assessment. To be included in analysis participants must have complete Monetary Incentive Delay (MID) data at both Baseline and post-baseline, without excessive head motion. Participants with MID \<40% at baseline were excluded from the analysis and summary statistics. Scores were not bounded by a minimum or maximum range, higher z-score implies a greater motivation of the participant by the prospect of monetary gain than no monetary gain.

  Baseline, Day 15

Secondary Outcomes (2)

• Plasma Concentrations of PF-06412562 for Each Dose.

  6, and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day 16

• Plasma Concentrations of PF-06663872 at for Each Dose.

  6 and 12 hours on Days 1, 7 and 12, as well as 0 hours on Day16

Study Arms (4)

PF-06412562 3mg

EXPERIMENTAL

PF-06412562 3mg BID

Drug: PF-06412562 3mg BID

PF-06412562 9mg

EXPERIMENTAL

PF-06412562 9mg BID

Drug: PF-06412562 9mg BID

PF-06412562 45mg

EXPERIMENTAL

PF-06412562 45mg BID

Drug: PF-06412562 45mg BID

Placebo

PLACEBO COMPARATOR

Placebo BID

Other: Placebo

Interventions

PF-06412562 3mg BID DRUG

PF-06412562

Also known as: PF-06412562 3mg

PF-06412562 3mg

PF-06412562 9mg BID DRUG

PF-06412562

Also known as: PF-06412562 9mg

PF-06412562 9mg

PF-06412562 45mg BID DRUG

PF-06412562

Also known as: PF-06412562 45mg

PF-06412562 45mg

Placebo OTHER

Placebo

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects with schizophrenia both male and female
• Evidence of stable schizophrenia symptomatology for at least 3 months (no hospitalizations for schizophrenia, no increase in level of psychiatric care due to worsening of symptoms of schizophrenia, etc).
• Subjects must be in ongoing maintenance antipsychotic therapy other than clozapine (oral or depot) on a stable medication treatment regimen for for at least 2 months prior to Day 1, including concomitant psychotropic medications.

You may not qualify if:

• History of seizure
• Pregnant or nursing females
• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of screening and at the time of dosing).

Sponsors & Collaborators

• Pfizer: lead

Study Sites (6)

Arcadia MRI & Imaging Center

Arcadia, California, 91007, United States

Location

California Clinical Trials Medical Group

Glendale, California, 91206, United States

Location

Glendale Adventist Medical Center

Glendale, California, 91206, United States

Location

Maryland Psychiatric Research Center (MPRC) of the University of Maryland

Baltimore, Maryland, 21228, United States

Location

CBH Health, LLC

Gaithersburg, Maryland, 20877, United States

Location

Foers Long Term Care Pharmacy LLC

Rockville, Maryland, 20850, United States

Location

Related Publications (1)

• Arce E, Balice-Gordon R, Duvvuri S, Naylor M, Xie Z, Harel B, Kozak R, Gray DL, DeMartinis N. A novel approach to evaluate the pharmacodynamics of a selective dopamine D1/D5 receptor partial agonist (PF-06412562) in patients with stable schizophrenia. J Psychopharmacol. 2019 Oct;33(10):1237-1247. doi: 10.1177/0269881119855302. Epub 2019 Jul 2.

  PMID: 31264510 DERIVED

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Schizophrenia

Interventions

BID protein, human

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders

Results Point of Contact

• Title: Pfizer ClinicalTrials.gov Call Center
• Organization: Pfizer, Inc.

ClinicalTrials.gov_Inquiries@pfizer.com

1-800-718-1021

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 23, 2015
• First Posted: April 16, 2015
• Study Start: April 1, 2015
• Primary Completion: October 1, 2016
• Study Completion: October 1, 2016
• Last Updated: February 4, 2019
• Results First Posted: February 4, 2019

Record last verified: 2019-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (6)